Video

Dr. Petrylak on Enzalutamide's Role in Prostate Cancer

Daniel P. Petrylak, MD, from the Smilow Cancer Center, discusses the recent approval and future role of enzalutamide for patients with prostate cancer.

Daniel P. Petrylak, MD, director, Prostate and Genitourinary Cancer Program, co-director, Signal Transduction Research Program, at the Smilow Cancer Center at Yale-New Haven, discusses his excitement over the recent approval of enzalutamide (Xtandi) for patients with metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with docetaxel and hormonal therapy.

Petrylak believes the approval of enzalutamide validates the theory that further manipulation of the hormone axis leads to improved outcomes. In addition to the recent approval, enzalutamide is currently being investigated earlier in the treatment process, similarly to abiraterone acetate (Zytiga).

One of the advantages of enzalutamide is that it can be given without the co-administration of a corticosteroid, Petrylak explains. This is beneficial because the immunotherapy sipuleucel-T (Provenge) requires at least one month following corticosteroid administration before the leukapheresis process can begin. Removing this added wait time will improve outcomes for patients, Petrylak believes.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine